# Multi-epitope constructs and antigen processing

Source: https://onco.cc/terms/multi-epitope-constructs/  
OnCo record `multi-epitope-constructs` (Term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A construct can encode several intended immune targets. Each target still needs to be processed, displayed and recognized in the tested biological setting.

## Summary

A primary multiepitope DNA-vaccine study found that flanking sequence changes altered processing efficiency and measured immunogenicity of encoded epitopes. That was evidence from the tested constructs, not a validated rule for every RNA cancer vaccine. The number of encoded epitopes is distinct from the number naturally displayed or recognized. Processing evidence, immune-response breadth and clinical outcome remain separate parts of a construct claim.

A computational study of spacer design for class-I-restricted string-of-beads polypeptides reported a fivefold increase in predicted epitope recovery and a 44 per cent reduction in predicted neo-epitope immunogenicity compared with designs without spacers (Schubert and Kohlbacher); these are predictions, not measured protection. Combining an N-terminal leader peptide with an MHC class I trafficking signal at the C terminus improved presentation of class I and class II epitopes in human and mouse dendritic cells and expanded antigen-specific CD8 and CD4 T cells in vitro and in mice (Kreiter and colleagues). In a first-in-human RNA poly-neo-epitope melanoma study all patients developed T-cell responses against multiple vaccine neo-epitopes (Sahin and colleagues; abstract only), and each patient's vaccine in the Rojas pancreatic cancer trial used two uridine mRNA strands, each encoding up to 10 neoepitopes. Mass spectrometry can identify recovered HLA-bound peptides. Caron and colleagues' 2015 review describes class I peptides predominantly 9 to 12 amino acids long and reports that about 10 per cent of acquired spectra could be confidently assigned at a 1 per cent false discovery rate in the workflows discussed. It also describes evidence that mass spectrometry underestimates the self-HLA peptide repertoire, so non-detection does not prove absence. Prediction is not presentation: of more than 1,300 amino acid changes in two mouse tumour models about 13 per cent were predicted to bind MHC class I and a small fraction of those were confirmed by mass spectrometry (Yadav and colleagues). Because a single amino acid after an epitope changed its immunogenicity in a multiepitope DNA vaccine (Livingston and colleagues, already linked), a changed spacer is a changed construct that needs renewed processing and display evidence, while earlier evidence is retained for the parts that did not change.

## Fields

- Kind: Term
- Last checked: 2026-11-09
- Also known as: polyepitope constructs; multi-epitope vaccine design

## Notes

- An encoded antigen window is not necessarily the peptide eventually displayed. Joined windows and spacers can create new junction sequences. A protein-routing signal concerns the encoded protein rather than the particle delivery address. Identify any intended helper segment and test its HLA class II presentation and CD4 response in the relevant setting. Verify sequence and expression, recovered HLA-bound peptides and functional recognition separately; prediction scores do not supply a presentation threshold. Changing a spacer changes the construct even if two selected windows are unchanged. More encoded targets create opportunities only where relevant antigen expression, processing, compatible HLA presentation and functional recognition can occur. Target count alone is not measured response breadth.

## Sources

- Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines.: https://doi.org/10.1016/s0264-410x(01)00233-x
- T cells compete for access to antigen-bearing antigen-presenting cells.: https://doi.org/10.1084/jem.192.8.1105
- Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.: https://doi.org/10.1182/blood-2006-04-015024
- Designing string-of-beads vaccines with optimal spacers.: https://doi.org/10.1186/s13073-016-0263-6
- Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.: https://doi.org/10.4049/jimmunol.180.1.309
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.: https://doi.org/10.1038/nature23003
- Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.: https://doi.org/10.1038/s41586-023-06063-y
- Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry.: https://doi.org/10.1074/mcp.o115.052431
- Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.: https://doi.org/10.1038/nature14001

## Connected records

- terms: [Codon optimization](https://onco.cc/terms/codon-optimization/), [Immune measurements and product evidence](https://onco.cc/terms/immune-product-evidence/), [Immunodominance](https://onco.cc/terms/immunodominance/), [Messenger RNA construct anatomy](https://onco.cc/terms/mrna-construct-anatomy/), [Peptide binding, presentation and immune recognition](https://onco.cc/terms/binding-presentation-recognition/)

---
JSON: https://onco.cc/api/v1/entities/multi-epitope-constructs.json